Strategic Initiative

Slingshot members are tracking this corporate initiative:

Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
TEVA Community voting in process
AbCellera Community voting in process

Additional Information

Additional Relevant Details Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and is eligible to receive undisclosed downstream milestones associated with the development and approval of therapeutic antibodies.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Feb 02, 2016
Projected Implementation:
Q1, 2016
Relevance Tracked Until:
Q1, 2017
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Monoclonal Antibodies